Ownership / Regenerative Medical Technology Group Inc. | Tables in SEC filings

RMTG Regenerative Medical Technology Group Inc.

Quarterly report

Below is a summary of the results of operations for the three months ended September 30, 2024 and 2023.

	For the Three Months Ended September 30,
	2024		2023		$ Change		% Change
Revenue	$	986,308	$	646,828	$	339,480		52.48	%
Cost of revenue		239,247		196,535		42,712		21.73	%
Gross profit		747,061		450,293		296,768		65.91	%

Operating expenses
Advertising and marketing		94,434		93,227		1,207		1.29	%
Professional fees		254,170		161,628		92,542		57.26	%
Officer compensation		22,500		22,500		-		0.00	%
Depreciation and
amortization expense		88,828		98,667		(9,839)		-9.97	%
Investor relations		3,403		2,250		1,153		51.24	%
General and administrative		264,077		147,084		116,993		79.54	%
Total operating expenses		727,412		525,356		202,056		38.46	%

Other income (expense)
Interest expense		(905,572)		(1,657,600)		(752,028)		-45.37	%
Gain (loss) on derivative
financial instruments		(1,222)		964		(2,186)		-226.76	%
Impairment of goodwill		-		(4,125,460)		4,125,460		-100.00	%
Net loss	$	(887,146)	$	(5,857,159)	$	(4,970,013)		-84.85	%

	Series AA Preferred Stock				Series DD Preferred Stock				Common Stock				Additional Paid In		Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit		Total
Balance July 1, 2024		1,050,000	$	1,050		9,870	$	10		12,493,938	$	12,494	$	40,181,074	$	(66,027,770)	$	(25,833,142)
Issuance of common stock for conversion of note		-		-		-		-		45,050		45		1,756		-		1,801
Net loss		-		-		-				-		-		-		(887,146)		(887,146)
Balance, September 30, 2024		1,050,000	$	1,050		9,870	$	10		12,538,968	$	12,539	$	40,182,830	$	(66,914,916)	$	(26,718,487)

	For the Nine Months Ended September 30,
	2024		2023
Training	$	400,792	$	462,277
Product supplies		1,236,472		981,756
Equipment		121,225		155,480
Patient procedures		838,182		194,872
Total revenue	$	2,596,671	$	1,794,385

Table search / Ownership / Regenerative Medical Technology Group Inc.